Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
AIDS and Behavior
Published in: AIDS and Behavior 3/2016

01-03-2016 | Original Paper

Adherence to Tobacco Dependence Treatment Among HIV-Infected Smokers

Authors: Kristine K. Browning, Mary Ellen Wewers, Amy K. Ferketich, Philip Diaz, Susan L. Koletar, Nancy R. Reynolds

Published in: AIDS and Behavior | Issue 3/2016

Login to get access

Abstract

High prevalence of tobacco use and low success in quitting remain significant problems for reducing disease burden among HIV-infected persons. This study’s purpose was to examine participant responsiveness and tobacco dependence treatment adherence and their influences on tobacco abstinence among HIV-infected patients. This non-randomized study included HIV-infected smokers 18 years of age or older, who smoked at least 5 cigarettes per day, and had an interest in quitting smoking in the next 30 days. HIV-infected smokers (n = 247) received a 12-week tobacco dependence treatment intervention that included pharmacotherapy and telephone counseling. Younger age and non-White race were associated with lower adherence to pharmacotherapy. Younger age, non-White race, and increased monthly binge drinking were associated with lower adherence to telephone counseling. High participant responsiveness was associated with adherence to pharmacotherapy, counseling, and abstinence. Development and testing of interventions to improve adherence to evidence-based tobacco dependence treatment is warranted.
Literature
1.
Patel N, Talwar A, Reichert VC, Brady T, Jain M, Kaplan MH. Tobacco and HIV. Clin Occup Environ Med. 2006;5(1):193–207.PubMed
2.
Diaz PT, King MA, Pacht ER, Wewers MD, Gadek JE, Nagaraja HN, et al. Increased susceptibility to pulmonary emphysema among HIV-seropositive smokers. Ann Intern Med. 2000;132:369–72.CrossRefPubMed
3.
Diaz PT, Wewers MD, Pacht E, Drake J, Nagaraja HN, Clanton TL. Respiratory symptoms among HIV-seropositive individuals. Chest. 2003;123(6):1977–82.CrossRefPubMed
4.
Kirk GD, Merlo C, O’Driscoll P, Mehta SH, Galai N, Vlahov D, et al. HIV infection is associated with an increased risk for lung cancer, independent of smoking. Clin Infect Dis. 2007;45(1):103–10.CrossRefPubMedPubMedCentral
5.
Miguez-Burbano MJ, Ashkin D, Rodriguez A, Duncan R, Pitchenik A, Quintero N, et al. Increased risk of Pneumocystis carinii and community-acquired pneumonia with tobacco use in HIV disease. Int J Infect Dis. 2005;9(4):208–17.CrossRefPubMed
6.
Sigel K, Wisnivesky J, Gordon K, Dubrow R, Justice A, Brown ST, et al. HIV as an independent risk factor for incident lung cancer. AIDS. 2012;26(8):1017–25.CrossRefPubMedPubMedCentral
7.
Helleberg M, Gerstoft J, Afzal S, Kronborg G, Larsen CS, Pedersen C, et al. Risk of cancer among HIV-infected individuals compared to the background population: impact of smoking and HIV. AIDS. 2014;28(10):1499–508.CrossRefPubMed
8.
Crothers K, Huang L, Goulet JL, Goetz MB, Brown ST, Rodriguez-Barradas MC, et al. HIV infection and risk for incident pulmonary diseases in the combination antiretroviral therapy era. Am J Respir Crit Care Med. 2011;183(3):388–95.CrossRefPubMedPubMedCentral
9.
Gordin FM, Roediger MP, Girard PM, Lundgren JD, Miro JM, Palfreeman A, et al. Pneumonia in HIV-infected persons: increased risk with cigarette smoking and treatment interruption. Am J Respir Crit Care Med. 2008;178(6):630–6.CrossRefPubMedPubMedCentral
10.
Kohli R, Lo Y, Homel P, Flanigan TP, Gardner LI, Howard AA, et al. Bacterial pneumonia, HIV therapy, and disease progression among HIV-infected women in the HIV epidemiologic research (HER) study. Clin Infect Dis. 2006;43(1):90–8.CrossRefPubMed
11.
Benard A, Mercie P, Alioum A, Bonnet F, Lazaro E, Dupon M, et al. Bacterial pneumonia among HIV-infected patients: decreased risk after tobacco smoking cessation. ANRS CO3 Aquitaine Cohort, 2000-2007. PLoS ONE. 2010;5(1):e8896.CrossRefPubMedPubMedCentral
12.
Fitch KV, Lo J, Abbara S, Ghoshhajra B, Shturman L, Soni A, et al. Increased coronary artery calcium score and noncalcified plaque among HIV-infected men: relationship to metabolic syndrome and cardiac risk parameters. J Acquir Immune Defic Syndr. 2010;55(4):495–9.CrossRefPubMedPubMedCentral
13.
Lang S, Mary-Krause M, Cotte L, Gilquin J, Partisani M, Simon A, et al. Increased risk of myocardial infarction in HIV-infected patients in France, relative to the general population. AIDS. 2010;24(8):1228–30.CrossRefPubMed
14.
Durand M, Sheehy O, Baril JG, Lelorier J, Tremblay CL. Association between HIV infection, antiretroviral therapy, and risk of acute myocardial infarction: a cohort and nested case-control study using Quebec’s public health insurance database. J Acquir Immune Defic Syndr. 2011;57(3):245–53.CrossRefPubMed
15.
U.S. Department of Health and Human Services. Tobacco use: prevention, cessation and control. 2006 September 5, 2006.
16.
Petoumenos K, Worm S, Reiss P, de Wit S, d’Arminio Monforte A, Sabin C, et al. Rates of cardiovascular disease following smoking cessation in patients with HIV infection: results from the D:A: D study(*). HIV Med. 2011;12(7):412–21.CrossRefPubMedPubMedCentral
17.
18.
Gritz ER, Vidrine DJ, Lazev AB, Amick BC 3rd, Arduino RC. Smoking behavior in a low-income multiethnic HIV/AIDS population. Nicotine Tob Res. 2004;6(1):71–7.CrossRefPubMed
19.
Niaura R, Shadel WG, Morrow K, Tashima K, Flanigan T, Abrams DB. Human immunodeficiency virus infection, AIDS, and smoking cessation: the time is now. Clin Infect Dis. 2000;31(3):808–12.CrossRefPubMed
20.
Mamary EM, Bahrs D, Martinez S. Cigarette smoking and the desire to quit among individuals living with HIV. AIDS Patient Care STDS. 2002;16(1):39–42.CrossRefPubMed
21.
Centers for Disease Control and Prevention (CDC). Current cigarette smoking among adults-United States, 2011. Morb Mortal Wkly Rep. 2012;61(44):891–4.
22.
Tesoriero JM, Gieryic SM, Carrascal A, Lavigne HE. Smoking among HIV positive New Yorkers: prevalence, frequency, and opportunities for cessation. AIDS Behav. 2010;14(4):824–35.CrossRefPubMed
23.
Mdodo R, Frazier EL, Dube SR, Mattson CL, Sutton MY, Brooks JT, et al. Cigarette smoking Prevalence among adults with HIV compared with the general adult population in the United States: cross-sectional surveys. Ann Intern Med. 2015;162(5):335–44.CrossRefPubMed
24.
Fiore MC, Jaén CR, Baker TB, et al. Treating tobacco use and dependence: 2008 update Clinical Practice Guideline. Rockville: US Department of Health and Human Services. Public Health Service; 2008.
25.
Humfleet GL, Hall SM, Delucchi KL, Dilley JW. A randomized clinical trial of smoking cessation treatments provided in HIV clinical care settings. Nicotine Tob Res. 2013;15(8):1436–45.CrossRefPubMedPubMedCentral
26.
Gritz ER, Danysh HE, Fletcher FE, Tami-Maury I, Fingeret MC, King RM, et al. Long-term outcomes of a cell phone-delivered intervention for smokers living with HIV/AIDS. Clin Infect Dis. 2013;57(4):608–15.CrossRefPubMedPubMedCentral
27.
28.
Shiffman S, Brockwell SE, Pillitteri JL, Gitchell JG. Use of smoking-cessation treatments in the United States. Am J Prev Med. 2008;34(2):102–11.CrossRefPubMed
29.
Alterman AI, Gariti P, Cook TG, Cnaan A. Nicodermal patch adherence and its correlates. Drug Alcohol Depend. 1999;53(2):159–65.CrossRefPubMed
30.
Cooper TV, DeBon MW, Stockton M, Klesges RC, Steenbergh TA, Sherrill-Mittleman D, et al. Correlates of adherence with transdermal nicotine. Addict Behav. 2004;29(8):1565–78.CrossRefPubMed
31.
Sabaté E. Adherence to long-term therapies- evidence for action. Switzerland: World Health Organization; 2003.
32.
Carroll C, Patterson M, Wood S, Booth A, Rick J, Balain S. A conceptual framework for implementation fidelity. Implement Sci. 2007;30(2):40.CrossRef
33.
Borrelli B. The assessment, monitoring, and enhancement of treatment fidelity in public health clinical trials. J Public Health Dent. 2011;71(s1):S52–63.CrossRefPubMedCentral
34.
Hood NE, Ferketich AK, Paskett ED, Wewers ME. Treatment adherence in a lay health adviser intervention to treat tobacco dependence. Health Educ Res. 2013;28(1):72–82.CrossRefPubMedPubMedCentral
35.
Webb MS, Vanable PA, Carey MP, Blair DC. Medication adherence in HIV-infected smokers: the mediating role of depressive symptoms. AIDS Educ Prev. 2009;21(3 Suppl):94–105.CrossRefPubMed
36.
Rao D, Feldman BJ, Fredericksen RJ, Crane PK, Simoni JM, Kitahata MM, et al. A structural equation model of HIV-related stigma, depressive symptoms, and medication adherence. AIDS Behav. 2011;16:711–6.CrossRef
37.
Venkatesh KK, Srikrishnan AK, Mayer KH, Kumarasamy N, Raminani S, Thamburaj E, et al. Predictors of nonadherence to highly active antiretroviral therapy among HIV-infected South Indians in clinical care: implications for developing adherence interventions in resource-limited settings. AIDS Patient Care STDS. 2010;24(12):795–803.CrossRefPubMedPubMedCentral
38.
Silverberg MJ, Leyden W, Quesenberry CP, Horberg MA. Race/ethnicity and risk of AIDS and death among HIV-infected patients with access to care. J Gen Intern Med. 2009;24(9):1065–72.CrossRefPubMedPubMedCentral
39.
Bird ST, Bogart LM, Delahanty DL. Health-related correlates of perceived discrimination in HIV care. AIDS Patient Care STDs. 2004;18(1):19–26.CrossRefPubMed
40.
Shuter J, Bernstein SL. Cigarette smoking is an independent predictor of nonadherence in HIV-infected individuals receiving highly active antiretroviral therapy. Nicotine Tob Res. 2008;10(4):731–6.CrossRefPubMed
41.
Gonzalez JS, Batchelder AW, Psaros C, Safren SA. Depression and HIV/AIDS treatment nonadherence: a review and meta-analysis. J Acquir Immune Defic Syndr. 2011;58(2):181–7.PubMed
42.
Gonzalez JS, Psaros C, Batchelder A, Applebaum A, Newville H, Safren SA. Clinician-assessed depression and HAART adherence in HIV-infected individuals in methadone maintenance treatment. Ann Behav Med. 2011;42(1):120–6.CrossRefPubMedPubMedCentral
43.
Sowah LA, Busse S, Amoroso A. HIV, tobacco use, and poverty: a potential cause of disparities in health status by race and socioeconomic status. J Health Care Poor Underserved. 2013;24(3):1215–25.CrossRefPubMed
44.
Shirley DK, Kesari RK, Glesby MJ. Factors associated with smoking in HIV-infected patients and potential barriers to cessation. AIDS Patient Care STDS. 2013;27(11):604–12.CrossRefPubMedPubMedCentral
45.
Bing EG, Burnam MA, Longshore D, Fleishman JA, Sherbourne CD, London AS, et al. Psychiatric disorders and drug use among human immunodeficiency virus-infected adults in the United States. Arch Gen Psychiatry. 2001;58(8):721–8.CrossRefPubMed
46.
Hays JT, Leischow SJ, Lawrence D, Lee TC. Adherence to treatment for tobacco dependence: association with smoking abstinence and predictors of adherence. Nicotine Tob Res. 2010;12(6):574–81.CrossRefPubMed
47.
Crothers K, Thompson BW, Burkhardt K, Morris A, Flores SC, Diaz PT, et al. HIV-associated lung infections and complications in the era of combination antiretroviral therapy. Proc Am Thorac Soc. 2011;8(3):275–81.CrossRefPubMedPubMedCentral
48.
SRNT Committee on Biochemical Verification. Biochemical verification of tobacco use and cessation. Nicotine Tobacco Res. 2002;4:149–59.CrossRef
49.
Cahill K, Stead LF, Lancaster T. Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev. 2012;4:CD006103.PubMed
50.
Swan GE, McClure JB, Jack LM, Zbikowski SM, Javitz HS, Catz SL, et al. Behavioral counseling and varenicline treatment for smoking cessation. Am J Prev Med. 2010;38(5):482–90.CrossRefPubMedPubMedCentral
51.
Food and Drug Administration. The smoking cessation aids varenicline (marketed as Chantix) and bupropion (marketed as Zyban and generics): suicidal ideation and behavior. FDA Drug Saf Newsl. 2009;2:1–4.
52.
Wewers ME, Ferketich AK, Harness J, Paskett ED. Effectiveness of a nurse-managed, lay-led tobacco cessation intervention among Ohio Appalachian women. Cancer Epidemiol Biomarkers Prev. 2009;18(12):3451–8.CrossRefPubMedPubMedCentral
53.
Kozlowski LT, Porter CQ, Orleans CT, Pope MA, Heatherton TF. Predicting smoking cessation with self-reported measures of nicotine dependence: FTQ, FTND, HSI. Drug Alcohol Depend. 1994;34:211–6.CrossRefPubMed
54.
Velicer WF, DiClemente CC, Prochaska JO, Brandenburg N. Decisional balance measure for assessing and predicting smoking status. J Pers Soc Psychol. 1985;48(5):1279–89.CrossRefPubMed
55.
Beck A, Ward C, Mendelson M, Mock J, Erbaugh J. Inventory for measuring depression. Arch Gen Psychiatry. 1961;4:561–71.CrossRefPubMed
56.
Ware JE, Kosinski M, Dewey JE, Gandek B. How to score and interpret single-item health status measures: A manual for users of the SF-8 health survey. Lincoln: Quality Metric Inc.; 2001.
57.
Roberts B, Browne J, Ocaka KF, Oyok T, Sondorp E. The reliability and validity of the SF-8 with a conflict-affected population in northern Uganda. Health Qual Life Outcomes. 2008;2(6):108.CrossRef
58.
Lefante JJ Jr, Harmon GN, Ashby KM, Barnard D, Webber LS. Use of the SF-8 to assess health-related quality of life for a chronically ill, low-income population participating in the Central Louisiana Medication Access Program (CMAP). Qual Life Res. 2005;14(3):665–73.CrossRefPubMed
59.
Bradley KA, Kivlahan DR, Bush KR, McDonell MB, Fihn SD. Variations on the CAGE Alcohol Sreening Questionnaire: strength and limitations in VA general medical patients. Alcohol Clin Exp Res. 2001;25(10):1472–8.CrossRefPubMed
60.
DiMatteo MR, Giordani PJ, Lepper HS, Croghan TW. Patient adherence and medical treatment outcomes: a meta-analysis. Med Care. 2002;40(9):794–811.CrossRefPubMed
61.
62.
63.
Pomerleau CS, Pomerleau OF, Majchrzak MJ, Kloska DD, Malakuti R. Relationship between nicotine tolerance questionnaire scores and plasma cotinine. Addict Behav. 1990;15:73–80.CrossRefPubMed
64.
Zhou W, Heist RS, Liu G, Park S, Neuberg DS, Asomaning K, et al. Smoking cessation before diagnosis and survival in early stage non-small cell lung cancer patients. Lung Cancer. 2006;53(3):375–80.CrossRefPubMed
65.
66.
Pacek LR, Latkin C, Crum RM, Stuart EA, Knowlton AR. Interest in quitting and lifetime quit attempts among smokers living with HIV infection. Drug Alcohol Depend. 2014;1(138):220–4.CrossRef
67.
Ong MK, Zhou Q, Sung HY. Primary care providers advising smokers to quit: comparing effectiveness between those with and without alcohol, drug, or mental disorders. Nicotine Tob Res. 2011;13(12):1193–201.CrossRefPubMedPubMedCentral
68.
Catz SL, Jack LM, McClure JB, Javitz HS, Deprey M, Zbikowski SM, et al. Adherence to varenicline in the COMPASS smoking cessation intervention trial. Nicotine Tob Res. 2011;13(5):361–8.CrossRefPubMedPubMedCentral
69.
Balmford J, Borland R, Hammond D, Cummings KM. Adherence to and reasons for premature discontinuation from stop-smoking medications: data from the ITC Four-Country Survey. Nicotine Tob Res. 2011;13(2):94–102.CrossRefPubMedPubMedCentral
70.
King G, Polednak A, Bendel RB, Vilsaint MC, Nahata SB. Disparities in smoking cessation between African Americans and Whites: 1990–2000. Am J Public Health. 2004;94(11):1965–71.CrossRefPubMedPubMedCentral
71.
Daza P, Cofta-Woerpel L, Mazas C, Fouladi RT, Cinciripini PM, Gritz ER, et al. Racial and ethnic differences in predictors of smoking cessation. Subst Use Misuse. 2006;41(3):317–39.CrossRefPubMed
72.
Fu SS, Kodl MM, Joseph AM, Hatsukami DK, Johnson EO, Breslau N, et al. Racial/ethnic disparities in the use of nicotine replacement therapy and quit ratios in lifetime smokers ages 25 to 44 years. Cancer Epidemiol Biomarkers Prev. 2008;17(7):1640–7.CrossRefPubMedPubMedCentral
73.
Carpenter MJ, Ford ME, Cartmell K, Alberg AJ. Misperceptions of nicotine replacement therapy within racially and ethnically diverse smokers. J Natl Med Assoc. 2011;103(9–10):885–94.CrossRefPubMedPubMedCentral
74.
Lacey L, Tukes S, Manfredi C, Warnecke RB. Use of lay health educators for smoking cessation in a hard-to-reach urban community. J Community Health. 1991;16(5):269–82.CrossRefPubMed
75.
Whittaker R, McRobbie H, Bullen C, Borland R, Rodgers A, Gu Y. Mobile phone-based interventions for smoking cessation. Cochrane Database Syst Rev. 2012;11:CD006611.PubMed
76.
Mermelstein R, Lichtenstein E, McIntyre K. Partner support and relapse in smoking-cessation programs. J Consult Clin Psychol. 1983;51(3):465–6.CrossRefPubMed
77.
Havassy BE, Hall SM, Wasserman DA. Social support and relapse: commonalities among alcoholics, opiate users, and cigarette smokers. Addict Behav. 1991;16(5):235–46.CrossRefPubMed
Metadata
Title
Adherence to Tobacco Dependence Treatment Among HIV-Infected Smokers
Authors
Kristine K. Browning
Mary Ellen Wewers
Amy K. Ferketich
Philip Diaz
Susan L. Koletar
Nancy R. Reynolds
Publication date
01-03-2016
Publisher
Springer US
Published in
AIDS and Behavior / Issue 3/2016
Print ISSN: 1090-7165
Electronic ISSN: 1573-3254
DOI
https://doi.org/10.1007/s10461-015-1059-1

Other articles of this Issue 3/2016

AIDS and Behavior 3/2016 Go to the issue

Original Paper

HIV, Hepatitis C, and Abstinence from Alcohol Among Injection and Non-injection Drug Users

Original Paper

Which Patient Characteristics Among Cocaine Users with HIV Relate to Drug Use and Adherence Outcomes Following a Dual-Focused Intervention?

Original Paper

Trends in Any and High-Dose Opioid Analgesic Receipt Among Aging Patients With and Without HIV

Original Paper

Armed Conflict, Substance Use and HIV: A Global Analysis

Original Paper

Trends and Predictors of Cigarette Smoking Among HIV Seropositive and Seronegative Men: The Multicenter Aids Cohort Study

Original Paper

Correlates of Alcohol Use Among Patrons of Alcohol Consumption Venues in Botswana

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24 to hear Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits